Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Senior Editor Cathy Kelly discuss what we learned, and did not learn, from the 15 August release of the first batch of drug prices negotiated by the US Centers for Medicare and Medicaid Services, as well as its impact on the program and industry going forward.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?